Prostate cancer: bisphosphonates, denosumab prevent bone loss from ADT

Access to the full content of this site is available only to registered healthcare professionals. Register to read more


  • Bisphosphonates increased bone mineral density (BMD) in men with nonmetastatic prostate cancer who received androgen deprivation therapy (ADT).
  • Denosumab increased BMD and also reduced risk for fracture in these men.

Why this matters

  • ADT is associated with risk for reduct...